Aligos Therapeutics, Inc.
ALGS
$7.22
-$0.43-5.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -69.59% | 81.56% | -12.36% | 2.05% | 46.52% |
| Total Depreciation and Amortization | 15.23% | -9.44% | -41.45% | -52.76% | -62.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.50% | -201.94% | 271.65% | 232.87% | -180.11% |
| Change in Net Operating Assets | 148.70% | 23.57% | 63.71% | 17.78% | 70.95% |
| Cash from Operations | -7.37% | -2.18% | 6.87% | 12.10% | 0.57% |
| Capital Expenditure | -345.19% | -236.15% | -242.20% | -116.84% | -28.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.71% | -106.01% | 59.47% | -8.96% | 141.53% |
| Cash from Investing | 56.57% | -106.94% | 58.62% | -9.15% | 141.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -18.75% | 83.13% | -22.73% | 18.33% | 29.67% |
| Issuance of Common Stock | -99.88% | 23,157.53% | 471.38% | 471.41% | 467.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.17% | 28,529.58% | 15.21% | 15.29% | 15.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.31% | 81.05% | 118.87% | 42.31% | 190.50% |